vaxart
announces
dosing
first
subject
phase
clinical
trial
oral
tablet
vaccine
dose
ranging
study
examine
safety
immunogenicity
first
clinical
data
readouts
weeks
south
san
francisco
globe
newswire
vaxart
nasdaq
vxrt
biotechnology
company
developing
oral
vaccines
administered
tablet
rather
injection
today
announced
first
subject
dosed
phase
study
oral
tablet
vaccine
candidate
advancing
clinical
development
based
strength
data
showed
vaccine
capable
inducing
robust
systemic
immune
response
strong
mucosal
immune
response
specifically
lungs
said
sean
tucker
chief
scientific
officer
founder
vaxart
eager
explore
clinical
profile
effective
protection
infection
transmission
healthy
phase
trial
designed
examine
safety
immunogenicity
two
doses
healthy
adult
volunteers
aged
years
old
enrollment
expected
completed
early
november
participants
receiving
low
high
dose
oral
tablet
days
safety
reactogenicity
immunogenicity
assessments
performed
set
times
active
phase
excited
oral
tablet
vaccine
entering
clinic
believe
pandemic
needs
oral
alternative
injectable
vaccines
said
andrei
floroiu
chief
executive
officer
vaxart
room
temperature
stable
oral
tablet
vaccine
potential
ease
many
problems
associated
distribution
administration
cold
chain
dependent
injectable
vaccines
may
make
herd
immunity
achievable
making
much
easier
vaccinate
people
faster
looking
forward
receiving
first
clinical
data
next
vaxart
vaxart
biotechnology
company
developing
range
oral
recombinant
vaccines
based
proprietary
delivery
platform
vaxart
vaccines
designed
administered
using
convenient
room
tablets
stored
shipped
without
refrigeration
eliminate
risk
injury
vaxart
demonstrated
proprietary
tablet
vaccine
delivery
platform
suitable
deliver
recombinant
vaccines
positioning
company
develop
oral
versions
currently
marketed
vaccines
design
recombinant
vaccines
new
indications
development
programs
currently
include
tablet
vaccines
designed
protect
coronavirus
norovirus
seasonal
influenza
respiratory
syncytial
virus
rsv
well
therapeutic
vaccine
human
papillomavirus
hpv
vaxart
first
indication
vaxart
filed
broad
domestic
international
patents
covering
proprietary
technology
creations
oral
vaccination
using
adenovirus
agonists
note
regarding
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
statements
historical
facts
included
press
release
regarding
vaxart
strategy
prospects
plans
objectives
results
preclinical
clinical
trials
commercialization
agreements
licenses
beliefs
expectations
management
statements
statements
may
accompanied
words
believe
could
potential
expected
plan
words
terms
similar
meaning
examples
statements
include
limited
statements
relating
vaxart
ability
develop
including
enrolling
sufficient
number
patients
manufacturing
sufficient
quantities
product
candidates
commercialize
vaccine
candidate
preclinical
clinical
results
trial
data
including
plans
respect
vaccine
product
candidates
expectations
regarding
timing
nature
future
announcements
including
related
clinical
trials
results
preclinical
studies
vaxart
expectations
respect
important
advantages
believes
oral
vaccine
platform
offer
injectable
alternatives
particularly
coronaviruses
potential
applicability
results
seen
vaxart
preclinical
trials
may
seen
human
studies
clinical
trials
expected
role
mucosal
immunity
blocking
transmission
vaxart
expectations
respect
effectiveness
products
product
candidates
including
vaxart
potential
role
mitigating
impact
globally
vaxart
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
statements
vaxart
makes
including
uncertainties
inherent
research
development
including
ability
meet
anticipated
clinical
endpoints
commencement
completion
dates
clinical
trials
preclinical
studies
regulatory
submission
dates
regulatory
approval
dates
launch
dates
well
possibility
unfavorable
new
clinical
data
analyses
existing
clinical
data
risk
clinical
trial
preclinical
study
data
subject
differing
interpretations
assessments
regulatory
authorities
whether
regulatory
authorities
satisfied
design
results
clinical
studies
decisions
regulatory
authorities
impacting
labeling
manufacturing
processes
safety
could
affect
availability
commercial
potential
product
candidate
including
possibility
vaxart
product
candidates
may
approved
fda
regulatory
authorities
even
approved
fda
regulatory
authorities
vaxart
product
candidates
may
achieve
broad
market
acceptance
vaxart
collaborator
may
attain
development
commercial
milestones
vaxart
partners
may
experience
manufacturing
issues
delays
due
events
within
outside
vaxart
partners
control
including
recent
outbreak
difficulties
production
particularly
scaling
initial
production
including
difficulties
production
costs
yields
quality
control
including
stability
product
candidate
quality
assurance
testing
shortages
qualified
personnel
key
raw
materials
compliance
strictly
enforced
federal
state
foreign
regulations
vaxart
may
able
obtain
maintain
enforce
necessary
patent
intellectual
property
protection
vaxart
capital
resources
may
inadequate
vaxart
ability
obtain
sufficient
capital
fund
operations
terms
acceptable
vaxart
impact
government
healthcare
proposals
policies
competitive
factors
risks
described
risk
factors
sections
vaxart
quarterly
annual
reports
filed
sec
vaxart
assume
obligation
update
statements
except
required
law
references
links
websites
provided
convenience
information
contained
website
part
incorporated
reference
press
release
vaxart
responsible
contents
websites
